Compare Invesco Preferred ETF (PGX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Invesco Preferred ETF trades at $10.76, while Regeneron Pharmaceuticals Inc trades at $653.5 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Invesco Preferred ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| PGX | REGN | |
|---|---|---|
52-Week High | $11.87 | $812.27 |
52-Week Low | $10.79 | $545.46 |
Market Cap | — | $70.79B |
Sector | — | Health |
Enterprise Value | — | $64.74B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $10.79, down 0.64% on the day, with a bearish technical outlook from moving averages. The ETF shows neutral momentum oscillators. Recent corporate actions include scheduled dividends for mid-2026. News highlights institutional selling and concerns over the fund's risk-return profile in the preferred stock space.
The outlook remains cautious due to structural subordination risks and interest rate sensitivity. Analyst sentiment is negative, citing capped upside and full participation in downturns. Key risks include credit defaults and macroeconomic shifts affecting preferred securities.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
